Literature DB >> 31982961

Clinical trial data validate the C-peptide estimate model in type 1 diabetes.

John M Wentworth1,2,3, Naiara G Bediaga4, Stephen E Gitelman5, Carmela Evans-Molina6, Peter A Gottlieb7, Peter G Colman8,9, Michael J Haller10, Leonard C Harrison4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31982961      PMCID： PMC8159479          DOI： 10.1007/s00125-020-05088-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.460


× No keyword cloud information.
  5 in total

1.  Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes.

Authors:  Marie Louise C Max Andersen; Philip Hougaard; Sven Pörksen; Lotte B Nielsen; Siri Fredheim; Jannet Svensson; Jane Thomsen; Jennifer Vikre-Jørgensen; Thomas Hertel; Jacob S Petersen; Lars Hansen; Henrik B Mortensen
Journal:  Pediatr Diabetes       Date:  2014-11       Impact factor: 4.866

2.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Authors:  Kevan C Herold; Brian N Bundy; S Alice Long; Jeffrey A Bluestone; Linda A DiMeglio; Matthew J Dufort; Stephen E Gitelman; Peter A Gottlieb; Jeffrey P Krischer; Peter S Linsley; Jennifer B Marks; Wayne Moore; Antoinette Moran; Henry Rodriguez; William E Russell; Desmond Schatz; Jay S Skyler; Eva Tsalikian; Diane K Wherrett; Anette-Gabriele Ziegler; Carla J Greenbaum
Journal:  N Engl J Med       Date:  2019-06-09       Impact factor: 91.245

3.  Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Authors:  Michael J Haller; Desmond A Schatz; Jay S Skyler; Jeffrey P Krischer; Brian N Bundy; Jessica L Miller; Mark A Atkinson; Dorothy J Becker; David Baidal; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Kevan C Herold; Jennifer B Marks; Antoinette Moran; Henry Rodriguez; William Russell; Darrell M Wilson; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2018-07-16       Impact factor: 19.112

Review 4.  Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.

Authors:  John M Wentworth; Naiara G Bediaga; Lynne C Giles; Mario Ehlers; Stephen E Gitelman; Susan Geyer; Carmella Evans-Molina; Leonard C Harrison
Journal:  Diabetologia       Date:  2018-08-30       Impact factor: 10.122

5.  Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.

Authors:  Carla J Greenbaum; Thomas Mandrup-Poulsen; Paula Friedenberg McGee; Tadej Battelino; Burkhard Haastert; Johnny Ludvigsson; Paolo Pozzilli; John M Lachin; Hubert Kolb
Journal:  Diabetes Care       Date:  2008-07-15       Impact factor: 19.112
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.